BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 18586363)

  • 1. An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals.
    Hewetson JF; Little SF; Ivins BE; Johnson WM; Pittman PR; Brown JE; Norris SL; Nielsen CJ
    Vaccine; 2008 Aug; 26(33):4262-6. PubMed ID: 18586363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109.
    Gu M; Hine PM; James Jackson W; Giri L; Nabors GS
    Vaccine; 2007 Jan; 25(3):526-34. PubMed ID: 16973247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Passive immunotherapy of Bacillus anthracis pulmonary infection in mice with antisera produced by DNA immunization.
    Herrmann JE; Wang S; Zhang C; Panchal RG; Bavari S; Lyons CR; Lovchik JA; Golding B; Shiloach J; Lu S
    Vaccine; 2006 Jul; 24(31-32):5872-80. PubMed ID: 16790303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series.
    Pittman PR; Norris SL; Barrera Oro JG; Bedwell D; Cannon TL; McKee KT
    Vaccine; 2006 Apr; 24(17):3654-60. PubMed ID: 16497418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques.
    Klinman DM; Xie H; Little SF; Currie D; Ivins BE
    Vaccine; 2004 Jul; 22(21-22):2881-6. PubMed ID: 15246624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of anti-protective antigen IgG subclass distribution in recipients of anthrax vaccine adsorbed (AVA) and patients with cutaneous and inhalation anthrax.
    Semenova VA; Schmidt DS; Taylor TH; Li H; Steward-Clark E; Soroka SD; Ballard MM; Quinn CP
    Vaccine; 2007 Feb; 25(10):1780-8. PubMed ID: 17229495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine-induced protection against anthrax in cheetah (Acinonyx jubatus) and black rhinoceros (Diceros bicornis).
    Turnbull PC; Tindall BW; Coetzee JD; Conradie CM; Bull RL; Lindeque PM; Huebschle OJ
    Vaccine; 2004 Sep; 22(25-26):3340-7. PubMed ID: 15308358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation and long term performance characteristics of a quantitative enzyme linked immunosorbent assay (ELISA) for human anti-PA IgG.
    Semenova VA; Schiffer J; Steward-Clark E; Soroka S; Schmidt DS; Brawner MM; Lyde F; Thompson R; Brown N; Foster L; Fox S; Patel N; Freeman AE; Quinn CP
    J Immunol Methods; 2012 Feb; 376(1-2):97-107. PubMed ID: 22197974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparability of ELISA and toxin neutralization to measure immunogenicity of Protective Antigen in mice, as part of a potency test for anthrax vaccines.
    Parreiras PM; Sirota LA; Wagner LD; Menzies SL; Arciniega JL
    Vaccine; 2009 Jul; 27(33):4537-42. PubMed ID: 19501205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of antibodies to squalene: III. Naturally occurring antibodies to squalene in humans and mice.
    Matyas GR; Rao M; Pittman PR; Burge R; Robbins IE; Wassef NM; Thivierge B; Alving CR
    J Immunol Methods; 2004 Mar; 286(1-2):47-67. PubMed ID: 15087221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine.
    Grunow R; Porsch-Ozcürümez M; Splettstoesser W; Buckendahl A; Hahn U; Beyer W; Böhm R; Huber M; vd Esche U; Bessler W; Frangoulidis D; Finke EJ
    Vaccine; 2007 May; 25(18):3679-83. PubMed ID: 17287051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the immune response induced by a nasal anthrax vaccine based on the protective antigen protein in anaesthetized and non-anaesthetized mice.
    Sloat BR; Cui Z
    J Pharm Pharmacol; 2006 Apr; 58(4):439-47. PubMed ID: 16597361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a competitive enzyme linked immunosorbent assay to identify epitope specific antibodies in recipients of the U.S. licensed anthrax vaccine.
    Gubbins MJ; Schmidt L; Tsang RS; Berry JD; Kabani A; Stewart DI
    J Immunoassay Immunochem; 2007; 28(3):213-25. PubMed ID: 17613668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial.
    Gorse GJ; Keitel W; Keyserling H; Taylor DN; Lock M; Alves K; Kenner J; Deans L; Gurwith M
    Vaccine; 2006 Aug; 24(33-34):5950-9. PubMed ID: 16797805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of early immune response-survival relationship in cynomolgus macaques after Anthrax Vaccine Adsorbed vaccination and Bacillus anthracis spore challenge.
    Sivko GS; Stark GV; Tordoff KP; Taylor KL; Glaze E; VanRaden M; Schiffer JM; Hewitt JA; Quinn CP; Nuzum EO
    Vaccine; 2016 Dec; 34(51):6518-6528. PubMed ID: 27155494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the protective efficacy of recombinant protective antigen vaccine (GC1109)-immunized human sera using passive immunization in a mouse model.
    Jo SK; Ahn BE; Choi EH; Kang JE; An H; Oh MD; Rhie GE
    Vaccine; 2020 Feb; 38(7):1586-1588. PubMed ID: 31911031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization.
    Li H; Soroka SD; Taylor TH; Stamey KL; Stinson KW; Freeman AE; Abramson DR; Desai R; Cronin LX; Oxford JW; Caba J; Pleatman C; Pathak S; Schmidt DS; Semenova VA; Martin SK; Wilkins PP; Quinn CP
    J Immunol Methods; 2008 Apr; 333(1-2):89-106. PubMed ID: 18304568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CpG oligonucleotides accelerate and boost the immune response elicited by AVA, the licensed anthrax vaccine.
    Klinman DM
    Expert Rev Vaccines; 2006 Jun; 5(3):365-9. PubMed ID: 16827620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of anti-protective antigen salivary IgG antibodies in recipients of the US licensed anthrax vaccine.
    Bienek DR; Chang CK; Cohen ME
    Vaccine; 2007 Aug; 25(32):5978-84. PubMed ID: 17597265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine.
    Little SF; Ivins BE; Webster WM; Fellows PF; Pitt ML; Norris SL; Andrews GP
    Vaccine; 2006 Mar; 24(14):2530-6. PubMed ID: 16417950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.